WO2003055890A1

WO2003055890A1 - Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents

Info

Publication number: WO2003055890A1
Application number: PCT/US2002/041168
Authority: WO
Inventors: Jacques Dumas; Robert Sibley; Jill Wood
Original assignee: Bayer Pharmaceuticals Corporation
Priority date: 2001-12-21
Filing date: 2002-12-20
Publication date: 2003-07-10
Also published as: AU2002364211A1

Abstract

The compounds of the invention are thienopyrimidine derivatives of the formula (I):wherein X is OR3 or NR3R4; q, R1, R2, R3, and R4 are described in the specification. These compounds are useful for the inhibiting the prolylpeptidase, inducing apoptosis and treating cancer.

Description

Thienopyrimidine Derivative Compounds as Inhibitors of Prolylpeptidase, Inducers of Apoptosis and Cancer

Treatment Agents

DESCRIPTION OF THE INVENTION

The present invention relates to:

(1) thienopyrimidine derivative compounds or purified stereoisomers or stereoisomer mixtures of said compounds and salts or prodrug forms thereof;

(2) pharmaceutical compositions comprising one or more of the compounds or purified stereoisomers or stereoisomer mixtures of the invention, or their salts or prodrugs forms thereof, with a pharmaceutically acceptable ingredient;

(3) methods of preparing the thienopyrimidine derivative compounds of (1); and (4) methods for inhibiting prolylpeptidase, inducing apoptosis and treating cancer in mammals by administering an effective amount of (1) or (2) to a patient in need thereof.

Description of the Compounds The compounds described as being part of the invention are thienopyrimidine derivative compounds which have the structural formula (I) defined below:

^R CH₂)_q-R₂ N

(I) wherein,

X is OR₃ or NR₃IU; Ri is selected from the group consisting of hydrogen and -( -C5) alkyl;

R is selected from the group consisting of

(a) -(C₆-C₈) cycloalkyl;

(b) phenyl; and (c) a saturated or fully unsaturated four to eight membered heterocyclic ring containing one to three heteroatoms independently selected from the group consisting of oxygen and sulfur; wherein (a) - (c) are optionally substituted with one to three substituents selected from the group consisting of amino, cyano, halogen, hydroxy, nitro, -

(C1-C5) alkoxy, -(C1-C₅) alkylamino, -(CH₂)_nC(=O)R₅, -(CH₂)_nC(=O)OR₅, -

(CH₂)_nC(=O)NR₆R₇ and -(Cι-C₅) linear or branched alkyl optionally substituted by halogen;

R₃ is selected from the group consisting of hydrogen and -(Cι-C₅) alkyl;

R₄. is selected from the group consisting of: (a) -(CH₂)_m-A, where A is:

(al) -(C₃-C₈) cycloalkyl, optionally substituted with cyano, -(C₁-C₅) alkoxy, amino, -(C Cs) alkylamino, or hydroxy,

(a2) a saturated or fully unsaturated four to eight membered heterocyclic ring, containing one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring system contains at least one carbon atom and wherein said ring is optionally substituted with up to three substituents selected from the group consisting of amino, cyano, halogen, hydroxy, nitro, oxo, -(C₁-C₅) alkoxy, -(CVC₅) alkylamino, and -(C Cs) linear or branched alkyl optionally substituted by halogen, (a3) a fused bicyclo ring wherein one ring is a saturated or fully unsaturated five to six membered heterocyclic ring which contains one to three heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring contains at least one carbon atom, and the other ring is a saturated or fully unsaturated five to eight membered carbocycle, (a4) (C₆-C₁₀)-aryl substituted with a saturated or fully unsaturated five to six membered heterocyclic ring, containing one to two heteroatoms selected from the group consisting of nitrogen and oxygen,

(b) -(CH₂)_p-O-A, where A is: (bl) hydrogen,

(b2) -(Cι-C₅) linear or branched alkyl,

(b3) -(C₃-C₈) cycloalkyl, optionally substituted with cyano,

-(C₁-C₅) alkoxy-, amino, -(Cι-C₅) alkylamino, or hydroxy, (b4) a saturated or fully unsaturated four to eight membered heterocyclic ring, containing one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said ring contains at least one carbon atom, (b5) -(C₆-C₁₀)-aryl, wherein (b4) and (b5) are optionally substituted with up to three substituents selected from the group consisting of amino, cyano, halogen, hydroxy, nitro, oxo, -(CrC₅) alkoxy-, -(C₁-C5) alkylamino and -(C₁-C₅) linear or branched alkyl optionally substituted by halogen;

R₃ and ι form, together with the nitrogen to which they are attached, a saturated or fully unsaturated four to eight-membered heterocyclic ring, containing zero to four additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and wherein said ring structure contains at least one carbon atom and wherein said ring is optionally substituted by one to two substituents selected from the group consisting of amino, cyano, hydroxy, - (CrC₅) alkoxy-, -(Cι-C₅) alkylamino and -(Cι-C₅) linear or branched alkyl optionally substituted by halogen;

R₅ is:

(a) hydrogen, (b) -(C₁-C₅) linear or branched alkyl optionally substituted with halogen, or

(c) -(C₆-C₁o)-aryl optionally substituted with halogen;

R₆ and R₇ are independently selected from the group consisting of

(a) hydrogen,

(b) -(Cι-C₅) linear or branched alkyl, and

(c) phenyl, wherein (b) to (c) are optionally substituted with one to two substituents selected from the group consisting of

1) amino,

2) cyano,

3) halogen,

4) hydroxy, 5) nitro,

6) oxo,

7) -(C1-C5) alkoxy,

8) -( -C₅) alkylamino and

9) -(CrCs) linear or branched alkyl optionally substituted by halogen,

10) a four to eight membered saturated or fully unsaturated heterocyclic ring containing one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said ring contains at least one carbon atom, and 11) a fused bicyclo ring wherein one ring is a saturated or fully unsaturated four to eight membered heterocyclic ring which contains one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring contains at least one carbon atom, wherein said heterocyclic ring contains at least one carbon atom and the other ring is a saturated or fully unsaturated three to eight membered carbocycle; m and p are independently an integer from 0 - 5; n is an integer from 0 - 3; q is an integer from 0 - 1 ; and q + (m or p) equals an integer from 1 - 6;

or a purified stereoisomer or stereoisomer mixture of said compound or a salt of said compound or purified stereoisomer or stereoisomer mixture thereof.

Pharmaceutically acceptable salts of these compounds as well as commonly used prodrugs of these compounds are also within the scope of the invention.

Detailed Description

The preferred compounds of the invention have general formula (I) and are further defined below. In the following description of these preferred compounds, the definitions for the various groups and variables represent the preferred definitions when they differ from those as broadly defined above, and are to be understood as independent of each other.

The preferred compounds of the invention have the formula (I) )_q-R₂

(I) wherein,

X is NR₃R_t;

Ri is selected from the group consisting of hydrogen and -(Cι-C₅) alkyl; R₂ is selected from the group consisting of (a) -(C₆-C₈) cycloalkyl; (b) phenyl; and

(c) a fully unsaturated five membered heterocyclic ring containing one heteroatom independently selected from the group consisting of oxygen and sulfur; wherein (a) - (c) are optionally substituted with one to two substituents selected from the group consisting of cyano, halogen, -(Cι-C₅) alkoxy, -(Ci- C₅) alkylamino, -(CH₂)_nC(=O)R₅, -(CH₂)_nC(=O)OR₅, -(CH₂)_nC(=O)NR₆R₇ and -(C Cs) linear or branched alkyl optionally substituted by halogen;

R₃ is selected from the group consisting of hydrogen and -(C₁-C₅) alkyl;

i is selected from the group consisting of:

(a) -(CH₂)_m-A, where A is: (al) -(C₅-C₈) cycloalkyl, optionally substituted with -(Cι-C₅) alkoxy, or -(Cι-C₅) alkylamino, (a2) a saturated or fully unsaturated five to six membered heterocyclic ring, containing one to two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring system contains at least one carbon atom and wherein said ring is optionally substituted with up to two substituents selected from the group consisting of cyano, halogen, oxo, -(CrC₅) alkoxy, -(Cι-C₅) alkylamino, and -(Cι-C₅) linear or branched alkyl optionally substituted by halogen,

(a3) a fused bicyclo ring wherein one ring is a saturated or fully unsaturated five to six membered heterocyclic ring which contains one to two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring contains at least one carbon atom, and the other ring is a saturated or fully unsaturated five to eight membered carbocycle, (a4) phenyl substituted with a saturated or fully unsaturated five to six membered heterocyclic ring, containing one to two heteroatoms selected from the group consisting of nitrogen and oxygen,

(b) -(CH₂)_p-O-A, where A is: (bl) -(C₁-C₅) linear or branched alkyl,

(b2) a saturated or fully unsaturated five to six membered heterocyclic ring, containing one to two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said ring contains at least one carbon atom,

(b3) phenyl, wherein (b2) and (b3) are optionally substituted with up to two substituents selected from the group consisting of cyano, halogen, oxo, -(CrC₅) alkoxy-, -(CrC₅) alkylamino and -(C₁-C₅) linear or branched alkyl optionally substituted by halogen;

or,

R₃ and j form, together with the nitrogen to which they are attached, a saturated five to eight-membered heterocyclic ring, containing zero to one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein said ring structure contains at least one carbon atom and wherein said ring is optionally substituted by one to two substituents selected from the group consisting of -(CrC₅) alkoxy-, -(Cι-C₅) alkylamino and -(Cι-C₅) linear or branched alkyl optionally substituted by halogen;

Rs is:

(a) hydrogen,

(b) -(CrC₅) linear or branched alkyl optionally substituted with halogen, or

(c) -(C₆-Cιo)-aryl optionally substituted with halogen;

R₆ and R₇ are independently selected from the group consisting of

(a) hydrogen, (b) -(CrCs) linear or branched alkyl,

(c) phenyl, wherein (b) to (c) are optionally substituted with one to two substituents selected from the group consisting of 1) halogen,

2) oxo,

3) -(C₁-C₅) alkoxy, and

4) -(CrCs) linear or branched alkyl optionally substituted by halogen, 5) a five to six membered saturated or fully unsaturated heterocyclic ring containing one to two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said ring contains at least one carbon atom, and

6) a fused bicyclo ring wherein one ring is a saturated or fully unsaturated five to six membered heterocyclic ring which contains one to two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring contains at least one carbon atom, wherein said heterocyclic ring contains at least one carbon atom and the other ring is a saturated six membered carbocycle, and

m and p are independently an integer from 0 - 5; n is an integer from 0 - 3; q is an integer from 0 - 1 ; and q + (m or p) equals an integer from 1 - 6;

The more preferred compounds of the invention have general formula (I) and are further defined below. In the following description of these more preferred compounds, the definitions for the various groups and variables represent the more preferred definitions when they differ from those as broadly defined above, and are to be understood as independent of each other.

The more preferred compounds of the invention have the formula (I)

(I) wherein, X is NR3R4; Ri is hydrogen;

R₂ is selected from the group consisting of

(a) -(C₆) cycloalkyl; and

(b) phenyl; wherein (a) and (b) are optionally substituted with one to two substituents selected from the group consisting of halogen,

-(CH₂)_nC(=O)OR₅, -(CH₂)„C(=O)NR₆R₇ and -(C1-C5) linear or branched alkyl optionally substituted by halogen;

R₃ is hydrogen;

; is selected from the group consisting of: (a) -(CH₂)_m-A, where A is:

(al) -(C₆) cycloalkyl, optionally substituted with -(C1-C₅) alkoxy, (a2) a saturated or fully unsaturated five to six membered heterocyclic ring, containing one to two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring system contains at least one carbon atom and wherein said ring is optionally substituted with up to two substituents selected from the group consisting of halogen, oxo, -(C₁-C₅) alkoxy, and -(C₁-C₅) linear or branched alkyl optionally substituted by halogen,

(a3) a fused bicyclo ring wherein one ring is a saturated or fully unsaturated five to six membered heterocyclic ring which contains one to two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring contains at least one carbon atom, and the other ring is a fully unsaturated six membered carbocycle,

(a4) phenyl substituted with a saturated or fully unsaturated six membered heterocyclic ring, containing one to two heteroatoms selected from the group consisting of nitrogen and oxygen,

(b) -(CH₂)_p-O-A, where A is:

(bl) -(C₁-C₅) linear or branched alkyl, (b2) phenyl, wherein (b2) is optionally substituted with up to two substituents selected from the group consisting of halogen, -(C1-C₅) alkoxy, and - (C₁-C₅) linear or branched alkyl optionally substituted by halogen;

or,

R₃ and R₄ form, together with the nitrogen to which they are attached, a saturated five to six-membered heterocyclic ring, containing zero to one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein said ring structure contains at least one carbon atom and wherein said ring is optionally substituted by one to two substituents selected from the group consisting of -(C₁-C₅) alkoxy, and -(CrCs) linear or branched alkyl optionally substituted by halogen;

R₅ is:

(a) hydrogen,

(b) -(CrC₅) linear or branched alkyl, or

(c) phenyl optionally substituted with halogen;

R₆ and R₇ are independently selected from the group consisting of

(a) hydrogen,

(b) -(Cι-C₅) linear or branched alkyl,

(c) phenyl, wherein (c) is optionally substituted with one to two substituents selected from the group consisting of halogen, -(C₁-C₅) alkoxy, and -(C₁-C₅) linear or branched alkyl optionally substituted by halogen;

m and p are independently an integer from 0 - 3; n is an integer from 0 - 1 ; q is an integer from 0 - 1 ; and q + (m or p) equals an integer from 1 - 4;

Salts are especially the pharmaceutically acceptable salts of compounds of formulae (I) or (II) such as, for example, organic or inorganic acid addition salts of compounds of formulae

(I) or (II). Suitable inorganic acids include but are not limited to halogen acids (such as hydrochloric acid), sulfuric acid, or phosphoric acid. Suitable organic acids include but are not limited to carboxylic, phosphonic, sulfonic, or sulfamic acids, with examples including acetic acid, trifluoroacetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, 2- or 3-hydroxybutyric acid, γ-aminobutyric acid (GAB A), gluconic acid, glucosemonocarboxylic acid, benzoic acid, salicylic acid, phenylacetic acid, mandelic acid, methanesulfonic acid, trifluoromethanesulfonic acid, fumaric acid, oxalic acid, succinic acid, adipic acid, pimelic acid, suberic acid, azeiaic acid, malic acid, tartaric acid, citric acid, glucaric acid, galactaric acid, amino acids (such as glutamic acid, aspartic acid, N-methylglycine, acetytaminoacetic acid, N-acetylasparagine or N-acetylcysteine), pyruvic acid, acetoacetic acid, phosphoserine, and 2- or 3-glycerophosphoric acid.

In addition, pharmaceutically acceptable salts include acid salts of inorganic bases, such as salts containing alkaline cations (e.g., Li⁺ Na⁺ or K⁺), alkaline earth cations (e.g., Mg⁺², Ca⁺² or Ba⁺²), the ammonium cation, as well as acid salts of organic bases, including aliphatic and aromatic substituted ammonium, and quaternary ammonium cations such as those arising from protonation or peralkylation of triethylamine, NN-diethylamine, NN- dicyclohexylamine, pyridine, NN-dimethylaminopyridine (DMAP), 1,4- diazabicyclo[2.2.2]octane (DABCO), l,5-diazabicyclo[4.3.0]non-5-ene (DBN) and 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU).

Prodrugs are considered to be any covalently bonded carriers which release the active parent compound of formula (I) or (II) in vivo. Formation of prodrugs is well known in the art in order to enhance the properties of the parent compound; such properties include solubility, absorption, biostability and release time (see "Pharmaceutical Dosage Form and Drug Delivery Systems" (Sixth Edition), edited by Ansel et al., publ. by Williams & Wilkins, pgs. 27-29, (1995) which is hereby incorporated by reference).

Commonly used prodrugs of the disclosed compounds of formula (I) and (II) are designed to take advantage of the major drug biotransformation reactions and are also to be considered within the scope of the invention. Major drug biotransformation reactions include N- dealkylation, O-dealkylation, aliphatic hydroxylation, aromatic hydroxylation, N-oxidation, S-oxidation, deamination, hydrolysis reactions, glucuronidation, sulfation and acetylation (see Goodman and Gilman's The Pharmacological Basis of Therapeutics (Tenth Edition), editor Hardman et al, publ. by McGraw-Hill, pages 12-18, (2001), which is hereby incorporated by reference).

Definitions

The term "halogen" as it appears in the specification and claims refers to fluorine, chlorine, bromine, and iodine substituents for the purposes of this invention. When halogen is a possible substituent on an alkyl group, the alkyl may be fully substituted, up to perhalo.

The term "fused bicyclo ring" as it appears in the specification and claims refers to a substituent which is a two ring structure which share two carbon atoms. The bonding between the fused bicyclo ring and the compound and/or atom to which it is attached can be through either of the two rings.

Description of Compositions The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of one or more of the compounds of formula (I) or purified stereoisomers or stereoisomer mixtures of the invention, or their salts or prodrugs forms thereof, with a pharmaceutically acceptable ingredient.

Compounds for the purpose of forming pharmaceutical compositions for the inhibiting apoptosis, inducing apoptosis or treating cancer also includes the compounds of formula (I) wherein A is optionally hydrogen and the remaining variables are as defined above. Brown et al. (U.S. Patent 5,280,026) disclosed compounds where A is hydrogen. However, these compounds were utilized as inhibitors of the Ε κ⁺ ATPase enzyme useful in the treatment of gastric acid secretion.

The pharmaceutical compositions are prepared so that they may be administered orally, dermaily, parenterally, nasally, ophthalmically, otically, sublingually, rectally or vaginally. Dermal administration includes topical application or transdermal administration. Parenteral administration includes intravenous, intraarticular, intramuscular, and subcutaneous injections, as well as use of infusion techniques. One or more compounds of the invention may be present in association with one or more non-toxic pharmaceutically acceptable ingredients and optionally, other active anti-proliferative agents, to form the pharmaceutical composition. These compositions can be prepared by applying known techniques in the art such as those taught in Remington's Pharmaceutical Sciences (Fourteenth Edition), Managing Editor, John E. Hoover, Mack Publishing Co., (1970) or Pharmaceutical Dosage Form and Drug Delivery Systems (Sixth Edition), edited by Ansel et al., publ. by Williams & Wilkins, (1995), each of which is hereby incorporated by reference.

Commonly used pharmaceutical ingredients which can be used as appropriate to formulate the composition for its intended route of administration include: acidifying agents (examples include but are not limited to acetic acid, citric acid, fumaric acid, hydrochloric acid, nitric acid); alkalinizing agents (examples include but are not limited to ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, triethanolamine, trolamine); adsorbents (examples include but are not limited to powdered cellulose and activated charcoal); aerosol propellants (examples include but are not limited to carbon dioxide, CC1₂F₂, F₂C1C- CC1F₂ and CC1F₃) air displacement agents (examples include but are not limited to nitrogen and argon); antifungal preservatives (examples include but are not limited to benzoic acid, butylparaben, ethylparaben, methylparaben, propylparaben, sodium benzoate); antimicrobial preservatives (examples include but are not limited to benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenylethyl alcohol, phenylmercuric nitrate and thimerosal); antioxidants (examples include but are not limited to ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorus acid, monothioglycerol, propyl gallate, sodium ascorbate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite); binding materials (examples include but are not limited to block polymers, natural and synthetic rubber, polyacrylates, polyurethanes, silicones and styrene-butadiene copolymers); buffering agents (examples include but are not limited to potassium metaphosphate, potassium phosphate monobasic, sodium acetate, sodium citrate anhydrous and sodium citrate dihydrate) carrying agents (examples include but are not limited to acacia syrup, aromatic syrup, aromatic elixir, cherry syrup, cocoa syrup, orange syrup, syrup, corn oil, mineral oil, peanut oil, sesame oil, bacteriostatic sodium chloride injection and bacteriostatic water for injection) chelating agents (examples include but are not limited to edetate disodium and edetic acid) colorants (examples include but are not limited to FD&C Red No. 3, FD&C Red No. 20, FD&C Yellow No. 6, FD&C Blue No. 2, D&C Green No. 5, D&C Orange No. 5, D&C Red No. 8, caramel and ferric oxide red); clarifying agents (examples include but are not limited to bentonite); emulsifying agents (examples include but are not limited to acacia, cetomacrogol, cetyl alcohol, glyceryl monostearate, lecithin, sorbitan monooleate, polyethylene 50 stearate); encapsulating agents (examples include but are not limited to gelatin and cellulose acetate phthalate) flavorants (examples include but are not limited to anise oil, cinnamon oil, cocoa, menthol, orange oil, peppermint oil and vanillin); humectants (examples include but are not limited to glycerin, propylene glycol and sorbitol); levigating agents (examples include but are not limited to mineral oil and glycerin); oils (examples include but are not limited to arachis oil, mineral oil, olive oil, peanut oil, sesame oil and vegetable oil); ointment bases (examples include but are not limited to lanolin, hydrophilic ointment, polyethylene glycol ointment, petrolatum, hydrophilic petrolatum, white ointment, yellow ointment, and rose water ointment); penetration enhancers (transdermal delivery) (examples include but are not limited to monohydroxy or polyhydroxy alcohols, saturated or unsaturated fatty alcohols, saturated or unsaturated fatty esters, saturated or unsaturated dicarboxylic acids, essential oils, phosphatidyl derivatives, cephalin, terpenes, amides, ethers, ketones and ureas) plasticizers (examples include but are not limited to diethyl phthalate and glycerin); solvents (examples include but are not limited to alcohol, corn oil, cottonseed oil, glycerin, isopropyl alcohol, mineral oil, oleic acid, peanut oil, purified water, water for injection, sterile water for injection and sterile water for irrigation); stiffening agents (examples include but are not limited to cetyl alcohol, cetyl esters wax, microcrystalline wax, paraffin, stearyl alcohol, white wax and yellow wax); suppository bases (examples include but are not limited to cocoa butter and polyethylene glycols (mixtures)); surfactants (examples include but are not limited to benzalkonium chloride, nonoxynol 10, oxtoxynol 9, polysorbate 80, sodium lauryl sulfate and sorbitan monopalmitate); suspending agents (examples include but are not limited to agar, bentonite, carbomers, carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, kaolin, methylcellulose, tragacanth and veegum); sweetening agents (examples include but are not limited to aspartame, dextrose, glycerin, mannitol, propylene glycol, saccharin sodium, sorbitol and sucrose); tablet anti-adherents (examples include but are not limited to magnesium stearate and talc); tablet binders (examples include but are not limited to acacia, alginic acid, carboxymethylcellulose sodium, compressible sugar, ethylcellulose, gelatin, liquid glucose, methylcellulose, povidone and pregelatinized starch); tablet and capsule diluents (examples include but are not limited to dibasic calcium phosphate, kaolin, lactose, mannitol, microcrystalline cellulose, powedered cellulose, precipitated calcium carbonate, sodium carbonate, sodium phosphate, sorbitol and starch); tablet coating agents (examples include but are not limited to liquid glucose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, cellulose acetate phthalate and shellac); tablet direct compression excipients (examples include but are not limited to dibasic calcium phosphate); tablet disintegrants (examples include but are not limited to alginic acid, carboxymethylcellulose calcium, microcrystalline cellulose, polacrillin potassium, sodium alginate, sodium starch glycollate and starch); tablet glidants (examples include but are not limited to colloidal silica, corn starch and talc); tablet lubricants (examples include but are not limited to calcium stearate, magnesium stearate, mineral oil, stearic acid and zinc stearate); tablet/capsule opaquants (examples include but are not limited to titanium dioxide); tablet polishing agents (examples include but are not limited to carnuba wax and white wax); thickening agents (examples include but are not limited to beewax, cetyl alcohol and paraffin); tonicity agents (examples include but are not limited to dextrose and sodium chloride); viscosity increasing agents (examples include but are not limited to alginic acid, bentonite, carbomers, carboxymethylcellulose sodium, methylcellulose, povidone, sodium alginate and tragacanth); and wetting agents (examples include but are not limited to heptadecaethylene oxycetanol, lecithins, polyethylene sorbitol monooleate, polyoxyethylene sorbitol monooleate, polyoxyethylene stearate,).

Depending on the route of administration, the compositions can take the form of aerosols, capsules, creams, elixirs, emulsions, foams, gels, granules, inhalants, lotions, magmas, ointments, peroral solids, powders, sprays, syrups, suppositories, suspensions, tablets and tinctures. The compositions of the invention can also have an additional apoptosis inducers as an active ingredient. Examples of known apoptosis inducers (see e.g. Calbiochem's 2001 Signal Transduction Catalog, pages 702-704, the contents of which are incorporated by reference) which can be added to the described invention include but are not limited to A23187, N-Acetyl-L-cysteine, actinomycin D, tyrphostin A9, tyrphostin A25, AG 490, AG 1714, anandamide, anisomycin, aphidicolin, bafilomycin Al, berberine hemisulfate, betulinic acid, bleomycin sulfate, CAFdA, calphostin C, camptothecin, CAPE, chelerythrine chloride, 2-chloro-2'-deoxyadenosine, 2-chloro-2'-deoxyadenosine 5'-triphosphate, colcemid, cochicine, corticosterone, cycloheximide, cyclophosphamide monohydrate, cyclosporine A, daunorubicin hydrocloride, dexamethasone, 3,3'-diindolylmethane, dolastatin 15, doxorubicin hydrochloride, erbstatin analog, ET-18-OCH₃, etoposide, etoposide phosphate, 5-fluorouracil, folimycin, forskolin, genistein, glycodeoxycholic acid sodium salt, H-7 dihydrochloride, H-89 dihydrochloride, harringtonine, homoharringtonine, 4- hydroxynonenal, 4-hydroxyphenylretinamide, hydroxyurea, indanocine, ionomycin free acid, ionomycin calcium salt, KN-93, methotrexate, mitomycin C, okadaic acid, oligomycin, p53 activator, paclitaxel, phorbol-12-myristate-13-acetate, (pivaloyloxy)methyl butyrate, puromycin dihydrochloride, 1-pyrrolidinecarbodithioic acid ammonium salt, quercetin dihydrate, rapamycin, SNAP, SNOG, sodium butyrate, sodium 4-phenylbutyrate, spermine tetrachloride,

(free base; N-Acetyl-; N,N-dimethyl-; N-hexanoyl-; and N-octanoyl forms), stautosporine, sulfasalizine, sulindac, tamoxifen citrate, 4-hydroxy- (Z)-tamoxifen, thapsigargin, α-toxin, TRAIL, valinomycin, (±)-verapamil hydrochloride, veratridine and vitamin E succinate.

Additional known apoptosis inducers (see Oncogene catalog, the contents of which are incoφorated by reference) include:

2β, 3β, 5β, Hot, 14α, 20R, 22R-Heptahydroxycholest-7-en-6-one, dactinomycin, DHAD;

1 ,4-dihydroxy-5,8-bw( {2-[(2-hydroxyethyl)amino])-9, 10-anthraquinone, 2HC1; N,N- hexamethylenebisacetamide (HMBA); mitoxanthrone, dihydrochloride; MurA; Muristerone A; NSC-301739; SAHA; suberoylanilide, hydroxamic acid; caspase-3 (Ab-4) Monoclonal

Antibody; active caspase-7 (Ab-1) Polyclonal Antibody; caspase-12 (Ab-1) Polyclonal

Antibody; caspase-12 (Ab-2) Polyclonal Antibody; caspase-13 (Ab-1) Polyclonal Antibody; acinus (Ab-1) Polyclonal Antibody; acinus (Ab-2) Polyclonal Antibody; acinus (Ab-3) Polyclonal Antibody; acinus (Ab-4) Polyclonal Antibody; AIF (Ab-1) Polyclonal Antibody; AIF (Ab-2) Polyclonal Antibody; Phospho-Bad (Ab-1) Polyclonal Antibody; Phospho-Bad (Ab-2) Polyclonal Antibody; Bid (Ab-1) Polyclonal Antibody; Bid (Ab-2) Polyclonal Antiserum; Bid (Ab-3) Polyclonal Antiserum; Bnip3L (Ab-1) Polyclonal Antibody; DRAK1 (Ab-1) Polyclonal Antibody; DRAK2 (Ab-1) Polyclonal Antibody; Fas (Ab-6) Polyclonal Antibody; FLASH (Ab-1) Polyclonal Antiserum; pi 10 Mitochondrial Protein (Ab-1) Monoclonal Antibody; pTEN (Ab-4) Polyclonal Antibody; Rb Associated Protein 46 (Ab-1) Polyclonal Antibody; Rb Associated Protein 48 (Ab-1) Polyclonal Antibody; RIP (Ab-1) Polyclonal Antibody; RIP2 (Ab-1) Polyclonal Antibody; Smac/DIABLO (Ab-3) Polyclonal Antibody; TWEAK (Ab-1) Polyclonal Antibody; NDAC (Ab-1) Polyclonal Antibody; Bad Control Proteins; and Fas Ligand Plus™ Recombinant Human Protein.

Optional cancer treatment agents which can be added to the composition include but are not limited to compounds listed on the cancer chemotherapy drug regimens in the 11^th Edition of the Merck Index, (1996), which is hereby incorporated by reference, such as asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin (adriamycine), epirubicin, etoposide, 5-fiuorouracil, hexamethylmelamine, hydroxyurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, prednisolone, prednisone, procarbazine, raloxifen, sfreptozocin, tamoxifen, thioguanine, topotecan, vinblastine, vincristine, and vindesine.

Other cancer treatment agents suitable for use with the composition of the invention include but are not limited to those compounds acknowldeged to be used in the treatment of neoplastic diseases in Goodman and Gilman's The Pharmacological Basis of Therapeutics (Tenth Edition), editor Hardman et al., publ. by McGraw-Hill, pages 1389-1459, (2001), which is hereby incorporated by reference, such as aminoglutethimide, anastrazole, L- asparaginase, azathioprine, 5-azacytidine cladribine, busulfan, camptothecin, diethylstilbestrol, docetaxel, erythrohydroxynonyladenine, ethinyl estradiol, exemestane, 5- fluorodeoxyuridine, 5-fluorodeoxyuridine monophosphate, fludarabine phosphate, fluoxyrnesterone, flutamide, formestane, hydroxyprogesterone caproate, gemcitabine, idarubicin, IL-2, α-interferon, letrozole, medroxyprogesterone acetate, megestrol acetate, melphalan, mitotane, oxaliplatin, paclitaxel, pentostatin, Ν-phosphonoacetyl-L-aspartate (PALA), plicamycin, semustine, teniposide, testosterone propionate, thiotepa, temozolomide, trimethylmelamine, uridine, vinorelbine and vorozole.

Other cancer treatment agents suitable for use with the composition of the invention include but are not limited to other anti-cancer agents such as epothilone.

For all regimens of use disclosed herein for compounds of formulae (I) or (II), the daily oral dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/kg of total body weight. The daily rectal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times daily. The transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/kg. The daily inhalation dosage regimen will preferably be from 0.01 to 100 mg/kg of total body weight.

It will be appreciated by those skilled in the art that the particular method of administration will depend on a variety of factors, all of which are considered routinely when administering therapeutics. It will also be understood, however, that the specific dose level for any given patient will depend upon a variety of factors, including, but not limited to the activity of the specific compound employed, the age of the patient, the body weight of the patient, the general health of the patient, the gender of the patient, the diet of the patient, time of administration, route of administration, rate of excretion, drug combinations, and the severity of the condition undergoing therapy. It will be further appreciated by one skilled in the art that the optimal course of treatment, i.e., the mode of treatment and the daily number of doses of a compound of formulae (la) or (Ila) or a pharmaceutically acceptable salt thereof given for a defined number of days, can be ascertained by those skilled in the art using conventional treatment tests. Description of Preparative Methods Abbreviations and Acronyms

The following terms have the indicated meanings.

DCM Dichloromethane

DMF NN-dimethylformamide eq equivalents

EtOAc ethyl acetate h hour

Hex hexanes

HPLC high performance liquid chromatography

LC liquid chromatography

Me methyl

MP melting point

MS mass spectra

NMR nuclear magnetic resonance rt room temperature

TLC thin layer chromatography

TFA trifluoroacetic acid

Experimental Section

Analytical data (1H ΝMR and LC-MS) for all compounds was in accordance with the described structure.

Unless otherwise stated, the term 'concentrated under reduced pressure' refers to use of a Buchi rotary evaporator at approximately 15 mm of Hg.

Thin-layer chromatography (TLC) was performed on Whatman^® pre-coated glass-backed silica gel 60A F-254 250 μm plates. Visualization of plates was effected by one or more of the following techniques: (a) ultraviolet illumination, (b) exposure to iodine vapor, (c) immersion of the plate in a 10% solution of phosphomolybdic acid in ethanol followed by heating, and/or (d) immersion of the plate in a cerium sulfate solution followed by heating. Column chromatography (flash chromatography) was performed using 230-400 mesh EM Science^® silica gel

Melting points (mp) were determined using a Thomas-Hoover melting point apparatus or a Mettler FP66 automated melting point apparatus and are uncorrected.

Proton (1H) nuclear magnetic resonance (NMR) spectra were measured with a General Electric GN-Omega 300 (300 MHz) spectrometer with either Me Si (δ 0.00) or residual protonated solvent (CHC1₃ δ 7.26; MeOH δ 3.30; DMSO δ 2.49) as standard. Carbon (¹³C) ΝMR spectra were measured with a General Electric GN-Omega 300 (75 MHz) spectrometer with solvent (CDC1₃ δ 77.0; d₃-MeOD; δ 49.0; d₆-DMSO δ 39.5) as standard.

HPLC - electrospray mass spectra (HPLC ES-MS) were obtained using a Hewlett-Packard 1100 HPLC equipped with a quaternary pump, a variable wavelength detector set at 254 nm, a YMC pro C-18 column (2 x 23 mm, 120 A), and a Finnigan LCQ ion trap mass spectrometer with electrospray ionization. Spectra were scanned from 120-1200 amu using a variable ion time according to the number of ions in the source. The eluents were A: 2% acetonitrile in water with 0.02% TFA and B: 2% water in acetonirile with 0.018% TFA. Gradient elution from 10% B to 95% over 3.5 minutes at a flowrate of 1.0 mL/min was used with an initial hold of 0.5 minutes and a final hold at 95% B of 0.5 minutes. Total ran time was 6.5 minutes.

Experimental Section

Example 1. Methyl 4-[({2-[(2-thienylmethyl)amino]thieno[3,2-d]pyrimidin-4- yl} amino)methyl] benzoate.

Step 1. 2,4-dichlorothiophenol[3,2-d]pyrimidine. A solution of dry DMF (8 mL) in POCl₃ (400 mL) was stirred at rt for 20 min. under Ar before it was added to thieno[3,2-d]pyrimidine-2,4-diol (100.0 g, 595 mmol). The suspension was heated to a gentle reflux. After 5 h, the resultant dark yellow solution was cooled to 70 °C and slowly poured into vigorously stirred cold (0 °C) water (4000 mL) at a rate that kept the internal temperature below 20 °C. A solid precipitated immediately, after 10 min, the solution was filtered. The cake was washed with water (4000 mL) and dried under high vacuum at 40 °C for 18 h to afford 2,4-dichlorothiophenol[3,2-d]pyrimidine (106 g, 87%) as a tan solid. TLC Rf = 0.64 (100% CH₂C1₂). Mass spectrum (HPLC/ES): m/e = 205 (M+l).

Step 2. Methyl 4-{[(2-chIorothieno[3,2-d]pyrimidin-4-yl)amino]methyl}benzoate.

A suspension of 2,4-dichlorothiophenol[3,2-d]pyrimidine (1.500 g, 7.32 mmol), methyl 4- (aminomethyl)benzoate hydrochloride (2.21 g, 10.97 mmol), and sodium acetate (3.60 g, 43.89 mmol) in water (50 mL) was refluxed vigorously for 1.5 h. A yellow precipitate forms soon after refluxing begins. The hot suspension is filtered through a coarse frit and the solid washed well with water (2 X 50 mL). The yellow solid was dried in vacuo under P₂O₅ to give methyl 4-{[(2-chlorothieno[3,2-d]pyrimidin-4-yl)amino]methyl}benzoate.in 91% yield (2.223 g, 6.660 mmol). TLC: Rf = 0.25 (33% EtOAc/hexane); HPLC/MS: [M+H]+obs = 334 @ tr = 2.76 min. (ESI+).

Step 3. Methyl 4-[({2-[(2-thienylmethyl)ammo]thieno[3,2-d]pyrimidin-4-yl}amino) methyljbenzoate. A neat solution of methyl 4-{[(2-chlorothieno[3,2-d]pyrimidin-4- , yl)amino]methyl}benzoate (175 mg, 0.524 mmol) in 2-aminomethylthiophene (593 mg, 5.24 mmol) was heated at 100 °C in a sealed vial for 20 h. The reaction was diluted with water (30 mL) and extracted with EtOAc (3 x 75 ml). The organic layers were dried (Na₂SO₄) and concentrated in vacuo to give a yellow oil. The crude product was purified by silica gel chromatography (33% EtOAc/hexane) to give an oil. The methyl 4-[({2-[(2- thienylmethyl)amino]thieno[3,2-d]pyrimidin-4-yl}amino)methyl]benzoate was obtained as a white solid by crystallization in CH₂C1₂ and hexane in 53% yield (114 mg, 0.278 mmol). TLC: Rf = 0.45 (50% EtOAc/hexane); HPLC/MS: [M+H]+obs = 411 @ tr = 2.28 min. (ESI+). Example 2. Methyl 4-[({2-[(2-phenoxyethyl)amino]thieno[3,2-d]pyrimidin-4- yl} amino)methyl]benzoate.

A solution of methyl 4-{[(2-chlorothieno[3,2-d]pyrimidin-4-yl)amino]methyl}benzoate (70 mg, 0.210 mmol), 2-phenoxyethylamine (1.19 g, 8.69 mmol), and catalytic 1% HCl (aq) (0.70 mL) was heated at 100 °C in a sealed vial for 72 h. The reaction was quenched with water (50 mL) and sat. NaHCO₃ (10 mL) and extracted with EtOAc (3 x 100 ml). The organics were dried (MgSO₄) and concentrated in vacuo to give a yellow oil. Purification by silica gel chromatography (33% EtOAc/hexane) afforded methyl 4-[({2-[(2- phenoxyethyl)amino]thieno[3,2-d]pyrimidin-4-yl}amino)methyl]benzoate as a white solid in 24% yield (22 mg, 0.051 mmol). TLC: Rf = 0.28 (50% EtOAc/hexane); HPLC/MS: [M+H]+obs = 435 @ tr = 2.43 min. (ESI+).

Example 3. 4-({[2-(Isobutylamino)thieno[3,2-d]pyrimidm-4-yI]amino}methyl) benzoic acid.

A solution of N-isobutyl-4-({[2-(isobutylamino)thieno[3,2-d]pyrimidin-4-yl]amino} methyl)benzamide (34 mg, 0.08 mmol) in cone. HCl (125 mL) was heated to reflux for 16 h. The reaction was concentrated under reduced pressure to give a white solid. This was suspended in water (10 mL) and sonicated well, then filtered washing well with water (2 x 5 mL), EtOAc (2 x 5 mL), then CH C1₂ (2 5 mL). The solid was dried in vacuo under P₂O₅ to give 4-({[2-(isobutylamino)thieno[3,2-d]pyrimidin-4-yl]amino}methyl) benzoic acid in 47 % yield (14 mg, 0.04 mmol). TLC: Rf = 0.10 (20% MeOH/EtOAc); HPLC/MS: [M+H]+obs = 357 @ tr = 2.14 min. (ESI+). Examples 3 - 37 in Table 1 were synthesized according to the above methods or by using other synthetic methods known in the art such as those described in the monograph series "The Chemistry of Heterocyclic Compounds", edited by Weissberger, The Pyrimidines, edited by D.J. Brown, publ. by Interscience Publishers, (1962) or the monograph series "The Chemistry of Heterocyclic Compounds", edited by Weissberger and Taylor, The Pyrimidines - Supplement I, edited by D.J. Brown, publ. by Interscience Publishers, (1970), and Vol. 52, The Pyrimidines, edited by D.J.Brown, Interscience Publishers, (1994), each of which is incorporated in its entirety by reference.

Table 1. Thienopyrimidines

Description of Inhibiting Prolylpeptidase, Inducing Apoptosis and Treatment of Cancer

Apoptosis (programmed cell death) is an essential process in the development and maintenance of homeostasis in an organism (1). The growth fraction of a tumor is governed by the rate of cellular division as well as the rate of cell death: if the rate of division exceeds that of cell death, then net tumor expansion occurs. Importantly, net growth rates of tumors do not generally correlate directly with the rate, of cell division within the tumor, as assessed by the abundance of mitotic figures. Hence, aberrant apoptotic rate plays an important role in tumor growth and expansion (2, 3).

Studies have demonstrated that cells transfected with either myc or ras oncogenes exhibit altered proliferation and apoptotic rates (4, 5). Transfectant cell lines that displayed elevated rates of both cell division and apoptosis lead to established tumors with reduced efficiency, compared to transfectant lines that displayed an elevated rate of cell division and reduced rate of apoptosis. Moreover, tumors with comparable mitotic indices exhibit radically different net growth rates depending on whether the basal apoptotic rates are low (yielding high tumor growth rates) or high (yielding low tumor growth rates). For example, low apoptotic rates are thought to drive the observed net growth rates observed in prostate cancer (6). Hence, targets that regulate apoptotic pathways in tumor cells should provide important points for novel therapeutic intervention and, should lead to an improved therapeutic effect (7).

Proteases are attractive cancer drug targets since they are known to regulate apoptotic signal transduction (8, 9). For example, work on apoptosis initiated by specific inhibitors of the proteasome complex has been reported in the literature, where lactacystin and other proteasome inhibitors are shown to cause apoptosis in a number of cell lines (10, 11).

Recent publications have identified prolylpeptidase (QPP) as an intracellular protease involved in the repression of apoptosis and, as such, prolylpeptidase is thought to be an anti- apoptotic factor (12, 13). Prolylpeptidase is a serine protease that is irreversibly inactivated by diispropyl-fluorophosphate (DFP) through covalent modification of Serl54 (12) and unpublished data. It is the only known human serine protease that is fully active without additional post-translational removal of inhibitory peptide. In addition, the enzyme is localized to novel non-lysosomal cytosolic vesicles (14). Recombinant prolylpeptidase as well as prolylpeptidase purified from natural sources are active as dimeric proteins (106 kDa), based on size exclusion chromatography, although the gene encodes a putative enzyme with a predicted mass of 58 kDa (15).

Active prolylpeptidase has been identified in a number of solid tumor cell lines of different histological types including those from colon (HCT116 and DLD1), prostate (PC3), and breast (MDA-MB-435). In addition, expression data for prolylpeptidase mRNA shows a very limited distribution across adult human tissues, with highest levels observed in the testis, and moderate levels in prostate, skeletal muscle and brain. Increased expression of prolylpeptidase mRNA in human tumor specimens and the published biological data on the enzyme suggest that prolylpeptidase plays an important role in tumor cell growth or survival. In summary, these data suggest that selective inhibition of prolylpeptidase activity in tumor cells could lead to increased apoptotic rates and growth inhibition.

Described below are the results of prolylpeptidase inhibition assays and apoptosis induction assays which show the effect of the applicants described compounds.

The prolylpeptidase enzyme used in the assay protocol cited below was described by Kapeller-Libermann et al. (U.S. Serial No. 09/345,469, the contents of which is hereby incorporated by reference; see also WO 01/00812).

Prolylpeptidase Assay Protocol

Test compounds were diluted serially 1:5 in 5% DMSO/95% water and 5 μL was added to give 100 μL as a final volume to a well containing prolylpeptidase enzyme in buffer. Drug had a final concentration ranging from 10 μM to 0.12 μM. The Ala-Pro- AFC dipeptide substrate (AFC is 7-amino-4-trifluoro-methylcoumarin) in MTEN buffer was used at a final concentration of 200 μL and the reaction was initiated with 10 nM final concentration of recombinant prolylpeptidase. The reaction was allowed to proceed for 20 min at room temperature and quenched with 20 μL of 1 M Glycine-HCl pH 2.5. The 96 well plates were read as an endpoint assay at an excitation of 400 nm and emission of 505 run. The final DMSO concentration was 0.25% in the assay. Ala-Pro-AFC is a dipeptide substrate with a conjugated AFC fluorophore at the C-terminus. Hydrolysis of the dipeptide substrate releases free AFC which is excited at 400 nm and emission of 505 nm in a spectrofluorometer.

Assay buffer is 50 mM MTEN Buffer pH 4.5 (50 n M MES, 25 mM Tris, 25 mM ethanolamine, 100 mM NaCl). Enzyme storage buffer was 50 mM Tris pH 7.0, 50% glycerol and was stored at -80 °C. It was diluted in assay buffer just prior to initiation of the assay.

All example compounds of formula (I) were tested in the above prolylpeptidase assay and were found to inhibit prolylpeptidase at or below a concentration of 10 μM.

Multiparameter Apoptosis Assay

The induction of apoptosis by prolylpeptidase inhibitors was measured in whole cells using the multiparameter apoptosis assay (MPA). The assay uses the ArrayScan II (Cellomics Inc.

Pittsburgh, PA) and the MPA application software to simultaneously measure three parameters of apoptosis 1.) nuclear fragmentation 2.) actin content and 3.) mitochondrial potential. Test compounds were dissolved in 100% DMSO and diluted serially 1:2 in

DMEM with 10% fetal calf serum (final DMSO concentration 0.25%) and added to HCT- 116 cells growing in 96-well tissue culture plates. The final drag concentrations ranged from 25 μM to 0.39 μM. Cells were exposed to compound for either one or 24 hours depending on the experiment. The MPA assay was run according to the manufactures' protocol. The % of control for each compound concentration is determined using the formula; %Control = (((Experimental Units)-Blank Units)/Units from untreated Control- Blank Units)* 100. A curve is fitted and a value for Y=50% (IC₅₀) using the formula

Y-A+((B-A)/(1+(((B-E)(X/C)^ΛD)/(E-A))). The average of the IC₅₀ values for nuclear fragmentation, actin content and mitochondria index is used as the MPA IC₅₀.

Example 15 was tested in the above apoptosis assay and found to induce apoptosis below a concentration of 25 μM.

References Cited

(All references cited are hereby incorporated by reference) 1. Lowe, S. W. and Lin, A. W. Apoptosis in cancer, Carcinogenesis. 21: 485- 95., 2000.

2. Kaufinann, S. H. and Gores, G. J. Apoptosis in cancer: cause and cure, Bioessays. 22: 1007-17., 2000. 3. Eastman, A. and Rigas, J. R. Modulation of apoptosis signaling pathways and cell cycle regulation, Semin Oncol. 26: 7-16; discussion 41-2., 1999.

4. Breckenridge, D. G. and Shore, G. C. Regulation of apoptosis by El A and Myc oncoproteins, Crit Rev Eukaryot Gene Expr. 10: 273-80., 2000.

5. Huang, P. and Oliff, A. Signaling pathways in apoptosis as potential targets for cancer therapy, Trends Cell Biol. 11: 343-8., 2001.

6. Colombel, M., Gil Diez, S., Radvanyi, F., Buttyan, R., Thiery, J. P., and Chopin, D. Apoptosis in prostate cancer. Molecular basis to study hormone refractory mechanisms, Ann N Y Acad Sci. 784: 63-9., 1996.

7. Penn, L. Z. Apoptosis modulators as cancer therapeutics, Curr Opin Investig Drugs. 2: 684-92., 2001.

8. Grimm, L. M. and Osborne, B. A. Apoptosis and the proteasome, Results Probl Cell Differ. 23: 209-28., 1999.

9. Masdehors, P., Merle-Beral, H., Magdelenat, H., and Delic, J. Ubiquitin- proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic ' death activation, Leuk Lymphoma. 38: 499-504., 2000.

10. Tani, E., Kitagawa, H., Ikemoto, H., and Matsumoto, T. Proteasome inhibitors induce Fas-mediated apoptosis by c-Myc accumulation and subsequent induction of FasL message in human glioma cells, FEBS Lett. 504: 53-8., 2001.

11. Naujokat, C., Sezer, O., Zinke, H., Leclere, A., Hauptmann, S., and Possinger, K. Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAFl/Cipl in human immature leukemic cells, Eur J Haematol. 65: 221-36., 2000.

12. Underwood, R., Chiravuri, M., Lee, H., Schmitz, T., Kabcenell, A. K., Yardley, K., and Huber, B. T. Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase, J Biol Chem. 274: 34053-8., 1999.

13. Chiravuri, M. and Huber, B. T. Aminodipeptidase inhibitor-induced cell death in quiescent lymphocytes: a review, Apoptosis. 5: 319-22., 2000. 14. Chiravuri, M., Agarraberes, F., Mathieu, S. L., Lee, H., and Huber, B. T. Vesicular localization and characterization of a novel post-proline-cleaving aminodipeptidase, quiescent cell proline dipeptidase, J Immunol. 165: 5695-702., 2000. 15. Chiravuri, M., Lee, H., Mathieu, S. L., and Huber, B. T. Homodimerization via a leucine zipper motif is required for enzymatic activity of quiescent cell proline dipeptidase, J Biol Chem. 275: 26994-9., 2000.

Other embodiments of the invention will be apparent to the skilled in the art from a consideration of this specification or practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with the scope and spirit of the invention being indicated by the following claims.

Claims

What is claimed is:

1. A compound of formula (I) :

R _/(CH )_q-R₂

N

(i) wherein,

X is OR₃ or NR₃R ;

Ri is selected from the group consisting of hydrogen and -(C₁-C5) alkyl;

R₂ is selected from the group consisting of (a) -(C₆-C₈) cycloalkyl;

(b) phenyl; and

(c) a saturated or fully unsaturated four to eight membered heterocyclic ring containing one to three heteroatoms independently selected from the group consisting of oxygen and sulfur; wherein (a) - (c) are optionally substituted with one to three substituents selected from the group consisting of amino, cyano, halogen, hydroxy, nitro, - (CrC₅) alkoxy, -( -C₅) alkylamino, -(CH₂)_nC O)R₅, -(CH₂)_nC(=O)OR₅, - (CH₂)_nC(=O)NR₆R₇ and -(CrC₅) linear or branched alkyl optionally substituted by halogen;

R₃ is selected from the group consisting of hydrogen and -(C₁-C5) alkyl;

t is selected from the group consisting of: (a) -(CH₂)_m-A, where A is: (al) -(C₃-C₈) cycloalkyl, optionally substituted with cyano,

-(CrCs) alkoxy, amino, -(C₁-C₅) alkylamino, or hydroxy,

(a2) a saturated or fully unsaturated four to eight membered heterocyclic ring, containing one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring system contains at least one carbon atom and wherein said ring is optionally substituted with up to three substituents selected from the group consisting of amino, cyano, halogen, hydroxy, nitro, oxo, -(CrCs) alkoxy, -(CrCs) alkylamino, and -(C₁-C₅) linear or branched alkyl optionally substituted by halogen,

(a3) a fused bicyclo ring wherein one ring is a saturated or fully unsaturated five to six membered heterocyclic ring which contains one to three heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring contains at least one carbon atom, and the other ring is a saturated or fully unsaturated five to eight membered carbocycle, (a4) (C₆-C₁₀)-aryl substituted with a saturated or fully unsaturated five to six membered heterocyclic ring, containing one to two heteroatoms selected from the group consisting of nitrogen and oxygen,

(b) -(CH₂)_p-O-A, where A is: (bl) hydrogen, (b2) -(CrCs) linear or branched alkyl,

(b3) -(C₃-C₈) cycloalkyl, optionally substituted with cyano,

-(C₁-C₅) alkoxy-, amino, -(C₁-C₅) alkylamino, or hydroxy, (b4) a saturated or fully unsaturated four to eight membered heterocyclic ring, containing one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said ring contains at least one carbon atom, (b5) -(C₆-C₁₀)-aryl, wherein (b4) and (b5) are optionally substituted with up to three substituents selected from the group consisting of amino, cyano, halogen, hydroxy, nitro, oxo, -( -Cs) alkoxy-, -(C₁-C₅) alkylamino and -(CrC₅) linear or branched alkyl optionally substituted by halogen; or,

R and _t form, together with the nitrogen to which they are attached, a saturated or fully unsaturated four to eight-membered heterocyclic ring, containing zero to four additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and wherein said ring structure contains at least one carbon atom and wherein said ring is optionally substituted by one to two substituents selected from the group consisting of amino, cyano, hydroxy, - (CrC₅) alkoxy-, -(CrCs) alkylamino and -(C₁-C₅) linear or branched alkyl optionally substituted by halogen;

Rs is:

(a) hydrogen,

(b) -(CrCs) linear or branched alkyl optionally substituted with halogen, or

(c) -(C₆-Cιo)-aryl optionally substituted with halogen;

R₆ and R₇ are independently selected from the group consisting of (a) hydrogen, (b) -(C₁-C₅) linear or branched alkyl, and

(c) phenyl, wherein (b) to (c) are optionally substituted with one to two substituents selected from the group consisting of 1) amino, 2) cyano,

3) halogen,

4) hydroxy,

5) nitro,

6) oxo, 7) -(C₁-C₅) alkoxy,

8) -(C₁-C₅) alkylamino and

9) -(C₁-C₅) linear or branched alkyl optionally substituted by halogen, 10) a four to eight membered saturated or fully unsaturated heterocyclic ring containing one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said ring contains at least one carbon atom, and 11) a fused bicyclo ring wherein one ring is a saturated or fully unsaturated four to eight membered heterocyclic ring which contains one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein said heterocyclic ring contains at least one carbon atom, wherein said heterocyclic ring contains at least one carbon atom and the other ring is a saturated or fully unsaturated three to eight membered carbocycle;

2. A pharmaceutical composition for the inhibition of prolylpeptidase, induction of apoptosis or the treatment of cancer which comprises a therapeutically effective amount of one or more compounds of claim 1 and a pharmaceutically acceptable excipient.

3. The pharmaceutical composition of claim 2 which further comprises an additional agent which induces apoptosis.

4. The pharmaceutical composition of claim 3 wherein the agent is selected from the group consisting of A23187, N-Acetyl-L-cysteine, actinomycin D, tyrphostin A9, tyrphostin A25, AG 490, AG 1714, anandamide, anisomycin, aphidicolin, bafϊlomycin Al, berberine hemisulfate, betulinic acid, bleomycin sulfate, CAFdA, calphostin C, camptothecin, CAPE, chelerythrine chloride, 2-chloro-2'- deoxyadenosine, 2-chloro-2'-deoxyadenosine 5'-triphosphate, colcemid, cochicine, corticosterone, cycloheximide, cyclophosphamide monohydrate, cyclosporine A, daunorubicin hydrocloride, dexamethasone, 3,3'-diindolylmethane, dolastatin 15, doxorabicin hydrochloride, erbstatin analog, ET-18-OCH₃, etoposide, etoposide phosphate, 5-fluorouracil, folimycin, forskolin, genistein, glycodeoxycholic acid sodium salt, H-7 dihydrochloride, H-89 dihydrochloride, harringtonine, homoharringtonine, 4-hydroxynonenal, 4-hydroxyphenylretinamide, hydroxyurea, indanocine, ionomycin free acid, ionomycin calcium salt, KN-93, methotrexate, mitomycin C, okadaic acid, oligomycin, p53 activator, paclitaxel, phorbol-12- myristate- 13 -acetate, (pivaloyloxy)methyl butyrate, puromycin dihydrochloride, 1- pyrrolidinecarbodithioic acid ammonium salt, quercetin dihydrate, rapamycin, SNAP, SNOG, sodium butyrate, sodium 4-phenylbutyrate, spermine tetrachloride, D-

(free base; N-Acetyl-; N,N-dimethyl-; N-hexanoyl-; and N- octanoyl forms), stautosporine, sulfasalizine, sulindac, tamoxifen citrate, 4-hydroxy-

(Z)-tamoxifen, thapsigargin, α-toxin, TRAIL, valinomycin, (±)-verapamil hydrochloride, veratridine and vitamin E succinate.

5. The pharmaceutical composition of claim 2 which further comprises an additional agent for the treatment of cancer.

6. The pharmaceutical composition of claim 5 wherein said additional agent for the treatment of cancer is selected from the group consisting of asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorabicin (adriamycine), epirabicin, etoposide, 5-fluorouracil, hexamethylmelamine, hydroxyurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, prednisolone, prednisone, procarbazine, raloxifen, sfreptozocin, tamoxifen, thioguanine, topotecan, vinblastine, vincristine, vindesine, aminoglutethimide, L-asparaginase, azathioprine, 5-azacytidine cladribine, busulfan, diethylstilbestrol, 2', 2'-difluorodeoxycytidine, docetaxel, erythrohydroxynonyladenine, ethinyl estradiol, 5-fluorodeoxyuridine, 5- fluorodeoxyuridine monophosphate, fludarabine phosphate, fluoxymesterone, flutamide, hydroxyprogesterone caproate, idarubicin, interferon, medroxyprogesterone acetate, megestrol acetate, melphalan, mitotane, paclitaxel, pentostatin, N-phosphonoacetyl-L-aspartate (PALA), plicamycin, semustine, teniposide, testosterone propionate, thiotepa, trimethylmelamine, uridine, vinorelbine, epothilone, irinotecan, raloxifen and topotecan.

7. A method of inhibiting prolylpeptidase which comprises administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.

8. A method of inhibiting prolylpeptidase which comprises administering to a patient in need thereof a therapeutically effective amount of the composition of claim 2.

9. A method of inducing apoptosis which comprises administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.

10. A method of inducing apoptosis which comprises administering to a patient in need thereof a therapeutically effective amount of the composition of claim 2.

11. A method of inducing apoptosis which comprises administering to a patient in need thereof a therapeutically effective amount of the composition of claim 3.

12. A method of inducing apoptosis which comprises administering to a patient in need thereof a therapeutically effective amount of the composition of claim 4.

13. A method of treating cancer which comprises administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.

14. A method of treating cancer which comprises administering to a patient in need thereof a therapeutically effective amount of the composition of claim 2.

15. A method of treating cancer which comprises administering to a patient in need thereof a therapeutically effective amount of the composition of claim 5. A method of treating cancer which comprises administering to a patient in need thereof a therapeutically effective amount of the composition of claim 6.